Review
Open access
Sep 2026
Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
BACKGROUND Despite advances in treatments multiple myeloma remains a therapeutically challenging disease. Although BCMA-directed therapies have improved outcomes, no standard exists after relapse. Teclistamab, a BCMA × CD3 bispecific antibody, redirects T cells to lyse myeloma cells and may overcome resistance to prior...
Hamzeh T. Al-Momany, Dani Zaid Kaylani, Omar H. Abuhashem et al.
· Current Problems in Cancer · 0 citations